Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report
Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage.
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …
[HTML][HTML] Moderate hypothermia to treat perinatal asphyxial encephalopathy
…, L Dyet, HL Halliday, E Juszczak… - … England Journal of …, 2009 - Mass Medical Soc
Background Whether hypothermic therapy improves neurodevelopmental outcomes in
newborn infants with asphyxial encephalopathy is uncertain. Methods We performed a …
newborn infants with asphyxial encephalopathy is uncertain. Methods We performed a …
[HTML][HTML] Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
…, WS Lim, A Montgomery, K Rowan, E Juszczak… - The Lancet, 2020 - thelancet.com
Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis
of in vitro activity, preclinical studies, and observational studies. Here, we report the results …
of in vitro activity, preclinical studies, and observational studies. Here, we report the results …
Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data
Objective To determine whether moderate hypothermia after hypoxic-ischaemic encephalopathy
in neonates improves survival and neurological outcome at 18 months of age. Design A …
in neonates improves survival and neurological outcome at 18 months of age. Design A …
[HTML][HTML] Donepezil and memantine for moderate-to-severe Alzheimer's disease
…, P Passmore, B Sheehan, E Juszczak… - … England Journal of …, 2012 - Mass Medical Soc
Background Clinical trials have shown the benefits of cholinesterase inhibitors for the
treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits …
treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits …
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
…, K Kossakowski, R Gill, E Juszczak… - The Lancet …, 2009 - thelancet.com
Background Data from 12-week placebo-controlled trials have led to mounting concerns
about increased mortality in patients with Alzheimer's disease (AD) who are prescribed …
about increased mortality in patients with Alzheimer's disease (AD) who are prescribed …
[HTML][HTML] Effects of hypothermia for perinatal asphyxia on childhood outcomes
…, J Goodwin, HL Halliday, E Juszczak… - … England Journal of …, 2014 - Mass Medical Soc
Background In the Total Body Hypothermia for Neonatal Encephalopathy Trial (TOBY),
newborns with asphyxial encephalopathy who received hypothermic therapy had improved …
newborns with asphyxial encephalopathy who received hypothermic therapy had improved …
Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial
J Fossey, C Ballard, E Juszczak, I James, N Alder… - Bmj, 2006 - bmj.com
Objective To evaluate the effectiveness of a training and support intervention for nursing home
staff in reducing the proportion of residents with dementia who are prescribed neuroleptics…
staff in reducing the proportion of residents with dementia who are prescribed neuroleptics…
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6,
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …